*Results from a retrospective analysis conducted to determine the relationship between uric acid levels and TLS in 1198 patients with a hematological malignancy who were admitted for inpatient chemotherapy.
Factors that put patients at increased risk of developing hyperuricemia and TLS include3-5:
Certain anticancer agents have been associated with elevated uric acid or TLS6-20†
|Brentuximab vedotin||Ixazomib||Cetuximab||Doxorubicin HCl‡|
|Pomalidomide||Vincristine sulfate‡||Thalidomide||Bendamustine HCl|
LDH=lactate dehydrogenase; WBC=white blood cell.
†This is not a comprehensive list of agents.
‡Components of the R-CHOP regimen.
WARNING: HYPERSENSITIVITY REACTIONS, HEMOLYSIS, METHEMOGLOBINEMIA, AND INTERFERENCE WITH URIC ACID MEASUREMENTS
ELITEK is contraindicated in patients with a history of anaphylaxis or severe hypersensitivity to rasburicase or in patients with development of hemolytic reactions or methemoglobinemia with rasburicase. ELITEK is contraindicated in individuals deficient in glucose-6-phosphate dehydrogenase (G6PD).
Most common adverse reactions (incidence ≥20%), when used concomitantly with anticancer therapy, are vomiting, nausea, fever, peripheral edema, anxiety, headache, abdominal pain, constipation, diarrhea, hypophosphatemia, pharyngolaryngeal pain, and increased alanine aminotransferase.
USE IN SPECIFIC POPULATIONS